| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
With the approval of ABRYSVO® for adults aged 18+, there is now a way to help protect against RSV in a population that previously did not have vaccination options.
Pfizer (PFE) Canada ULC announced today that Health Canada has approved a new indication for ABRYSVO®, the respiratory syncytial virus (RSV) stabilized prefusion F subunit bivalent vaccine, for use in adults aged 18-59 at increased risk for lower respiratory tract disease (LRTD) caused by RSV, in addition to existing indications of all adults over 60 and infants from birth through 6 months of age via maternal immunization. This milestone marks a significant expansion in RSV prevention, offering protection to a broader adult population previously without vaccine options.
ABRYSVO® addresses a substantial unmet need, as the first and only RSV vaccine indicated for adults 18 years and older. ABRYSVO® is also the only vaccine with a dual indication to help protect adults and infants form birth to 6 months of age through maternal immunization.
Posted In: PFE
